clopidogrel bioequivalence - PD endpoint [Design Issues]

posted by drks  – 2007-05-29 09:53 (6964 d 17:44 ago) – Posting: # 751
Views: 11,219

Dear All,

❝ As far as the european regulatory point of view, can we prove BE only with its inactive metabolite, as clopidogrel itself becomes BLQ after 2hrs post dose (As Per SmPC)?


Considering the difficulties with clopidogrel BE estimation,
  1. is it possible that the BE assessment be done on the basis of PD end points?
  2. Can platelet aggregation be utilised for estimating the bioequivalence of the clopidogrel?
  3. and most important, has there been any submission (and approval) of clopidogrel formulation to any regulatory agency?
I am aware that there are good methods for the estimation of clopidogrel now. However, we are exploring the possibility of PD studies to help in BE estimation of these formulations and i would appreciate if anybody could help in this regard.

Helmut, please share your comments on this.

best regards
kshitij

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
135 visitors (0 registered, 135 guests [including 32 identified bots]).
Forum time: 03:38 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5